Advertisement

Forensic Science, Medicine, and Pathology

, Volume 7, Issue 3, pp 248–252 | Cite as

“Ecstasy” associated deaths: what is a fatal concentration ? Analysis of a case series

  • C. M. MilroyEmail author
Original Article

Abstract

Amphetamine derivative drugs, particularly 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, are popular recreational drugs. MDMA is associated with causing death by a number of mechanisms, including hyperpyrexia, cardiac arrhythmia water intoxication and liver failure. Seventy-seven deaths where MDMA was detected in body fluids/organs were reviewed. Of these cases 59 deaths had MDMA present in blood. In 13 cases death was attributable to the toxic effects of MDMA alone with a range of 0.478–53.9 mg/l, mean 8.43 mg/l, median 3.49 mg/l. In 22 cases death was due to polydrug use, with an MDMA range of 0.04–41.5 mg/l, mean 2.90 mg/l, median 0.76 mg/l. In 24 cases death was due to trauma with an MDMA range of 0.035–4.81 mg/l, mean 0.862 mg/l, median 0. 483 mg/l. There is considerable overlap between the concentration of MDMA seen in deaths from direct MDMA toxicity and deaths associated with trauma. These findings show, that like other stimulant drugs, no specific concentration can be used to determine death without consideration of the history and full autopsy findings.

Keywords

3,4-methylenedioxymethamphetamine MDMA Ecstasy Toxicology Death Autopsy 

Notes

Acknowledgments

I would like to acknowledge the help of Ms L Jenkins, Department of Clinical Chemistry of the Royal Hallamshire Hospital, Sheffield for information on analytical techniques.

References

  1. 1.
    Centers for Disease Control and Prevention (CDC). Ecstasy overdoses at a New Year’s Eve rave–Los Angeles, California, 2010. MMWR Morb Mortal Wkly Rep. 2010;59:677–81.Google Scholar
  2. 2.
    Gill JR, Hayes JA, de Souza IS, Marker E, Stajic M. Ecstasy (MDMA) related deaths in New York City: a case series and review of the literature. J Forensic Sci. 2002;47:121–6.PubMedGoogle Scholar
  3. 3.
    Liu RH, Liu HC, Lin DL. Distribution of methylenedioxymethamphetamine (MDMA) and methylenedioxyamphetamine (MDA) in postmortem and antemortem specimens. J Anal Toxicol. 2006;30:545–50.PubMedGoogle Scholar
  4. 4.
    Lin DL, Liu HC, Liu RH. Methylenedioxymethamphetamine-related deaths in Taiwan: 2001–2008. J Anal Toxicol. 2009;33:366–71.PubMedGoogle Scholar
  5. 5.
    Verschraagen M, Maes A, Ruiter B, Bosman IJ, Smink BE, Lusthof KJ. Post-mortem cases involving amphetamine-based drugs in The Netherlands. Comparison with driving under the influence cases. Forensic Sci Int. 2007;170:163–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Hua YS, Liang R, Liang L, Huang GZ. Contraction band necrosis in two ecstasy abusers: a latent lethal lesion associated with ecstasy. Am J Forensic Med Pathol. 2009;30:295–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Sano R, Hasuike T, Nakano M, Kominato Y, Itoh H. A fatal case of myocardial damage due to misuse of the “designer drug” MDMA. Leg Med. 2009;11:294–7.CrossRefGoogle Scholar
  8. 8.
    Kaye S, Darke S, Duflou J. Methylenedioxymethamphetamine (MDMA)-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Drug Alcohol Depend. 2009;104:254–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Pilgrim JL, Gerostamoulos D, Drummer OH, Bollmann M. Involvement of amphetamines in sudden and unexpected death. J Forensic Sci. 2009;54:478–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving serotonergic drugs. Forensic Sci Int. 2010;198:110–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Shulgin A, Shulgin A. PIHKAL. A chemical love story. Berkeley: Transform Press; 1991.Google Scholar
  12. 12.
    Karch SB. A historical review of MDMA. Open Forensic Sci J (in press).Google Scholar
  13. 13.
    Perouka SJ. Incidence of recreational use of 3, 4 methylenedimethoxymethamphetamine (MDMA, “Ecstasy”) on an undergraduate campus. NEJM. 1987;317:1542–3.Google Scholar
  14. 14.
    Saunders N. Ecstasy reconsidered. London: Nicholas Saunders; 1997.Google Scholar
  15. 15.
    Collin M. Altered state. The story of ecstasy culture and acid house. London: Serpent’s Tail; 1997.Google Scholar
  16. 16.
    Common Illegal Drugs and their effects—cannabis, ecsasy, amphetamines and LSD. Parliamentary Office of Science and Technology; 1996.Google Scholar
  17. 17.
    Milroy CM. Ten years of “ecstasy”. J R Soc Med. 1999;92:68–72.Google Scholar
  18. 18.
    Forrest ARW, Galloway JH, Marsh ID, Strachan GA, Clark JC. A fatal overdose with 3, 4-methylenedioxymethamphetamine derivatives. Forensic Sci Int. 1994;64:57–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative deaths in South Australia—is “Ecstasy” the culprit? Am J Foreensic Med Pathol. 1998;19:261–5.CrossRefGoogle Scholar
  20. 20.
    Fineschi V, Masti A. Fatal poisoning by MDMA (ecstasy) and MDEA: a case report. Int J Leg Med. 1996;108:272–5.CrossRefGoogle Scholar
  21. 21.
    Wienman W, Bohnert M. Lethal monointoxication by overdosage of MDEA. Forensic Sci Int. 1998;91:91–101.CrossRefGoogle Scholar
  22. 22.
    Carter N, Rutty GN, Milroy CM, Forrest AR. Deaths associated with MBDB misuse. Int J Legal Med. 2000;113:168–70.PubMedCrossRefGoogle Scholar
  23. 23.
    Dowling GP, McDonough E, Bost R. Eve” and “ecstasy. A report of five deaths asociated with the use of MDEA and MDMA. JAMA. 1987;257:1615–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran, B. Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med. 1991;84:371.Google Scholar
  25. 25.
    Campkin NT, Daies UM. Another death from “ecstasy”. J R Soc Med. 1992;85:61.PubMedGoogle Scholar
  26. 26.
    Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”) Lancet. 1992;340:384–7.Google Scholar
  27. 27.
    Coore JR. A fatal trip with ecstasy: a case of 3, 4-methylenemethdioxyamphetamine/3, 4-methylenedioxyamphetamine. J R Soc Med. 1996;89:51–2.Google Scholar
  28. 28.
    Squier MV, Jalloh S, Hilton-Jones D, Series H. Death after ecstasy ingestion: neuropathological findings. J Neurol Neurosurg Psychiatry. 1995;58:756–64.PubMedCrossRefGoogle Scholar
  29. 29.
    Dar KJ, McBrien ME. MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med. 1996;22:995–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Milroy CM, Clark JC, Forrest ARW. The pathology of deaths associated with “Ecstasy” and “Eve” misuse. J Clin Pathol. 1996;49:149–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking “ecstasy”. BMJ. 1993;307:1399.PubMedCrossRefGoogle Scholar
  32. 32.
    Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3, 4-MDMA). Lancet. 1996;347:1052.PubMedCrossRefGoogle Scholar
  33. 33.
    Parr MJA, Low HM, Botterill P. Hyponatraemia and death after “ecstasy” ingestion. Med J Aus. 1997;166:143–6.Google Scholar
  34. 34.
    deMan RA, Wilson JH, Tjen HS. Acute liver failure caused by methylenedioxymethamphetamine (“ecstasy”). Ned Tijdschr Geneeskd 1993;137:727–9.Google Scholar
  35. 35.
    Dykhuizen RS, Brunt PW, Atkinson P, Simpson JG, Smith CC. Ecstasy induced hepatitis mimiking viral hepatitis. Gut. 1995;36:939–41.PubMedCrossRefGoogle Scholar
  36. 36.
    Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowman DA, Forsling M. Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet. 1998;351:1784.PubMedCrossRefGoogle Scholar
  38. 38.
    Karch SB, Stephens B, Ho CH. Relating cocaine blood concentrations to toxicity–an autopsy study of 99 cases. J Forensic Sci. 1998;43:41–5.Google Scholar
  39. 39.
    Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci. 1999;44:359–68.PubMedGoogle Scholar
  40. 40.
    Patel MM, Wright DW, Ratcliff JJ, Miller MA. Shedding new light on the “safe” club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208–10.PubMedGoogle Scholar
  41. 41.
    Furnari C, Ottaviano V, Rosati F, Tondi V. Identification of 3, 4-methlenedioxyamphetamine analogs encountered in clandestine tablets. Forensic Sci Int. 1998;92:49–58.PubMedCrossRefGoogle Scholar
  42. 42.
    Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ. Content of ecstasy in the Netherlands: 1993–2008. Addiction. 2009;104:2057–66.PubMedCrossRefGoogle Scholar
  43. 43.
    Elliott SP. MDMA and MDA concentrations in antemortem and postmortem specimens in fatalities following hospital admission. J Anal Toxicol. 2005;29:296–300.PubMedGoogle Scholar
  44. 44.
    De Letter EA, Bouche MP, Van Bocxlaer JF, Lambert WE, Piette MH. Interpretation of a 3, 4-methylenedioxymethamphetamine (MDMA) blood level: discussion by means of a distribution study in two fatalities. Forensic Sci Int. 2004;141:85–90.PubMedCrossRefGoogle Scholar
  45. 45.
    Krantz MJ, Mehler PS. QTc prolongation: methadone’s efficacy-safety paradox. Lancet. 2006;368(9535):556–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Eastern Ontario Forensic Pathology, Unit of the Ontario Forensic Pathology Service, Division of Anatomical PathologyThe Ottawa HospitalOttawaCanada
  2. 2.Department of Pathology and Laboratory MedicineUniversity of OttawaOttawaCanada

Personalised recommendations